Rotigotine in Parkinson's Disease Patients: What is the Efficient and Tolerable Dose According with the Real Clinical Practice? An Open, Non-Controlled Multicenter Spanish-Study

Abstract

Background: The efficacy and the tolerance of Rotigotine in PD patients has been shown in some studies published in the past. Nevertheless, there is few information in regards to the dose of Rotigotine used in the real clinical practice. Methods: We designed a multicenter, non-controlled, open follow up to study the efficient and tolerable doses of Roti-gotine used in the real clinical practice in mild impaired PD patients. Results: Patients included in this study showed a significant improvement in regards to the UPDRS motor scale, as well as in the PDQ-8 functional scale and the patient global impression scale at the end of the study. Whereas, the score in global clinical impression as well as in the NPI scale showed no significant statistical improvement at the end of the end of the study. Conclusions: PD patients of this study showed a motor and functional improvement after 3 months of Rotigotine transdermic patches therapy with a mean dose of 7.6 mg/daily and they experienced few and non-relevant adverse effects. the neuropsychiatric symptoms and impulse control disorders were rarely seen after Rotigotine therapy at 8 mgs/daily.